Origin and Epidemiological History of HIV-1 CRF14_BG

Authors: Abecasis AB, Barroso H, Bártolo I, Borrego P, Camacho R, Gomes P, McCutchan F, Taveira N
Journal: PLoS One
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=26&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1

Background: CRF14_BG isolates, originally found in Spain, are characterized by CXCR4 tropism and rapid disease progression. This study aimed to identify the origin of CRF14_BG and reconstruct its epidemiological history based on new isolates from Portugal.
Read More

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity

Authors: Barroso H, Borrego P, Calado R, Marcelino JM, Pereira P, Quintas A, Taveira N
Journal: AIDS
Link: http://www.ncbi.nlm.nih.gov/pubmed/23324659

To produce new fusion inhibitor peptides for HIV-1 and HIV-2 based on ancestral envelope sequences.
Read More

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Authors: Antunes F, Barroso H, Bártolo I, Borrego P, Caixas U, Calado R, Cavaco-Silva P, Doroana M, Maltez F, Marcelino JM, Rocha C, Taveira N
Journal: Antiviral Therapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Baseline+susceptibility+of+primary+HIV-2+to+entry+inhibitors

BACKGROUND:
The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown.
Read More

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.

Authors: Antunes F, Barroso H, Borrego P, Doroana M, Família C, Maltez F, Marcelino JM, Nilsson C, Quintas A, Taveira N
Journal: AIDS
Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Resistance+to+antibody+neutralization+in+HIV-2+infection+occurs+in+late+stage+disease+and+is+associated+with+X4+tropism

OBJECTIVES:
To characterize the nature and dynamics of the neutralizing antibody (NAb) response and escape in chronically HIV-2 infected patients.
Read More

Origin and Epidemiological History of HIV-1 CRF14_BG

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity

Baseline susceptibility of primary HIV-2 to entry inhibitors.

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.

About GHTM

Contacts

Funding